Statins in the prevention of heart failure after myocardial infarction

Current Heart Failure Reports

Volumn 6, Issue 4, 2009, Pages 215-219

  Glassberg, Helene ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIASTOLIC HEART FAILURE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EARLY INTERVENTION; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; MORTALITY; MYOPATHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; SIDE EFFECT; STROKE; SYSTOLIC HEART FAILURE;

HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

EID: 72449159327     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-009-0030-8     Document Type: Review

References (41)

1. P. Cannon E. Braunwald C.H. McCabe, et al. 2004 Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 1495 1504 10.1056/NEJMoa040583 1:CAS:528:DC%2BD2cXjtVeqtr8%3D 15007110 (Pubitemid 38477774)
2. J.C. LaRosa S.M. Grundy D.D. Waters, et al. 2005 Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 1425 1435 10.1056/NEJMoa050461 1:CAS:528:DC%2BD2MXjtVWltrw%3D 15755765 (Pubitemid 40471450)
3. T.R. Pedersen O. Faergeman J.J. Kastelein, et al. 2005 Highdose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL Study. A randomized controlled trial JAMA 294 2437 2445 10.1001/jama.294.19.2437 1:CAS:528:DC%2BD2MXht1aku7jK 16287954 (Pubitemid 41627921)
4. R. Laaksonen K. Jokelainen J. Laakso, et al. 1996 The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle Am J Cardiol 77 851 854 10.1016/S0002-9149(97)89180-1 1:CAS:528:DyaK28XjsFagsrc%3D 8623738
5. J. Kjekshus T.R. Pedersen A.G. Olsson, et al. 1997 The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease J Card Fail 3 249 254 10.1016/S1071-9164(97)90022-1 1:CAS:528: DyaK1cXisFGqtLg%3D 9547437 (Pubitemid 127674856)
6. B.M. Scirica D.A. Morrow C.P. Cannon, et al. 2006 Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT TIMI 22 study J Am Coll Cardiol 47 2326 2331 10.1016/j.jacc.2006.03.034 1:CAS:528:DC%2BD28Xmt12gu7o%3D 16750703 (Pubitemid 43795061)
7. T. Strandberg I. Holme O. Faergeman, et al. 2009 Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction Am J Cardiol 103 1381 1385 10.1016/j.amjcard.2009.01.377 1:CAS:528:DC%2BD1MXls12htrk%3D 19427432
8. E. Saab A. Fadi M. Petrina, et al. 2006 Early statin therapy in elderly patients presenting with acute coronary syndrome causing less heart failure Indian Heart J 58 321 324 19039148
9. T. Sakamoto S. Kojima H. Ogawa, et al. 2006 Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese Am J Cardiol 97 1165 1171 10.1016/j.amjcard. 2005.11.031 1:CAS:528:DC%2BD28XjsFOnsbs%3D 16616020
10. R.S. Wright K. Bybee W.L. Miller, et al. 2006 Reduced risks of death and CHF are associated with statin therapy administered acutely within the first 24 hours of AMI Int J Cardiol 108 314 319 10.1016/j.ijcard.2005.05.014 15975672 (Pubitemid 43339797)
11. K.K. Khush D.D. Waters V. Bitner, et al. 2007 Effect of high dose atorvastatin on hospitalization for heart failure: subgroup analysis of the treating to new targets (TNT) study Circulation 115 576 583 10.1161/ CIRCULATIONAHA.106.625574 1:CAS:528:DC%2BD2sXhtVyis74%3D 17261662 (Pubitemid 46226167)
12. M. Rauchhaus A.L. Clark W. Doehner, et al. 2003 The relationship between cholesterol and survival in patients with chronic heart failure J Am Coll Cardiol 42 1933 1940 10.1016/j.jacc.2003.07.016 1:CAS:528:DC%2BD2cXjt1Wksg%3D%3D 14662255 (Pubitemid 37485568)
13. T.B. Horwich M.A. Hamilton W.R. Maclellan G.C. Fonarow 2002 Low serum cholesterol is associated with marked increase in mortality in advance heart failure J Card Fail 8 216 224 10.1054/jcaf.2002.0804216 1:CAS:528: DC%2BD38XotlGnsrw%3D 12397569
14. Kleemann T: Long-term effects of statin therapy in patients with acute ST-elevation myocardial infarction and moderate or severe left ventricular dysfunction: reduction of mortality but not of nonfatal major adverse coronary and cerebrovascular events. Presented at the Annual Scientific Session of the American College of Cardiology. New Orleans, LA; March 7-10, 2004.
15. T.B. Horwich W.R. MacLellan G.C. Fonarow 2004 Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure J Am Coll Cardiol 43 642 648 10.1016/j.jacc.2003.07.049 1:CAS:528: DC%2BD2cXitlaqsbc%3D 14975476 (Pubitemid 38229538)
16. J.R. Emberson L.L. Ng J. Armitage, et al. 2007 N-terminal pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study J Am Coll Cardiol 49 311 319 10.1016/j.jacc.2006.08.052 17239712 (Pubitemid 46097374)
17. J. Kjekshus E. Apetrei V. Barrios, et al. 2007 Rosuvastatin in older patients with systolic heart failure N Engl J Med 357 2248 2261 10.1056/NEJMoa0706201 1:CAS:528:DC%2BD2sXhsVSlsLvI 17984166 (Pubitemid 350190755)
18. The GISSI-HF Investigators L. Tavazzi A.P. Maggioni 2008 The GISSI-HF trial: a randomized, double-blind, placebo-controlled trial Lancet 372 1231 1239 10.1016/S0140-6736(08)61240-4 18757089
19. H. Fukuta D.C. Sane S. Brucks, et al. 2005 Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report Circulation 112 357 363 10.1161/CIRCULATIONAHA.104.519876 1:CAS:528:DC%2BD2MXmtVWrtb0%3D 16009792 (Pubitemid 41022076)
20. F.A. Masoudi 2007 Statins for ischemic systolic heart failure N Engl J Med 357 2301 2304 10.1056/NEJMe0707221 1:CAS:528:DC%2BD2sXhsVSlu77J 17984167 (Pubitemid 350190763)
21. S.E. Nissen S.J. Nicholls I. Sipahi, et al. 2006 Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial JAMA 295 1556 1565 10.1001/jama.295.13.jpc60002 1:CAS:528:DC%2BD28Xjt12itrc%3D 16533939
22. P.M. Ridker C.P. Cannon D. Morrow, et al. 2005 C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 20 28 10.1056/NEJMoa042378 1:CAS:528:DC%2BD2MXis12msA%3D%3D 15635109 (Pubitemid 40075677)
23. K. Node M. Fujita M. Kitakaze, et al. 2003 Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy Circulation 108 839 843 10.1161/01.CIR.0000084539.58092.DE 1:CAS:528:DC%2BD3sXmtFCisbc%3D 12885745 (Pubitemid 37022126)
24. Y. Rikitake J.K. Liao 2005 Rho GTPases, statins and nitric oxide Circ Res 97 1232 1235 10.1161/01.RES.0000196564.18314.23 1:CAS:528:DC%2BD2MXht1yju7%2FL 16339495 (Pubitemid 43755179)
25. U. Laufs V. La Fata J. Plutzky, et al. 1998 Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors Circulation 97 1129 1135 1:CAS:528:DyaK1cXisVWmsrY%3D 9537338
26. K. Guo V. Andres K. Walsh 1998 Nitric oxide-induced down-regulation of Cdk2 activity and cyclin A gene transcription in vascular smooth muscle cells Circulation 97 2066 2072 1:CAS:528:DyaK1cXjslGnsb0%3D 9610538
27. R.U. Pliquett K.G. Cornish J.D. Peuler, et al. 2003 Simvastatin normalizes autonomic neural control in experimental heart failure Circulation 107 2493 2498 10.1161/01.CIR.0000065606.63163.B9 1:CAS:528:DC%2BD3sXjs1antLw%3D 12695293 (Pubitemid 36605234)
28. H. Mitani T. Bandoh J. Ishikawa, et al. 1996 Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits Br J Pharmacol 119 1269 1275 1:CAS:528:DyaK28Xntlentbs%3D 8937733
29. J. Bauersachs P. Galuppo D. Fraccarollo, et al. 2001 Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction Circulation 104 982 985 10.1161/hc3401.095946 1:CAS:528:DC%2BD3MXntlKisro%3D 11524389
30. J. Luo W.W. Zhang G.P. Zhang, et al. 1999 Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis Clin Exp Pharmacol Physiol 26 903 908 10.1046/j.1440-1681.1999.03165.x 1:CAS:528:DyaK1MXntFCktLs%3D 10561812 (Pubitemid 29513630)
31. R. Patel S.F. Nagueh N. Tsybouleva, et al. 2001 Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy Circulation 104 317 324 10.1161/hc2801.094031 1:CAS:528:DC%2BD3MXlslOmtL0%3D 11457751
32. Y. Kureishi Z. Luo I. Shiojima, et al. 2000 The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals Nat Med 6 1004 1010 10.1038/79510 1:CAS:528:DC%2BD3cXmslSjsL0%3D 10973320
33. N. Glorioso C. Troffa F. Filigheddu, et al. 1999 Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia Hypertension 34 1281 1286 1:CAS:528: DC%2BD3cXivFCkuw%3D%3D 10601131
34. B. Vrtovec R. Okrajsek A. Golicnik, et al. 2005 Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure J Card Fail 11 684 690 10.1016/j.cardfail.2005.06.439 1:CAS:528:DC%2BD2MXhtlWktLvJ 16360963 (Pubitemid 41797497)
35. A.P. Maggione 2001 Debate: should statins be used in patients with heart failure? Curr Control Trials Cardiovasc Med 2 226 227
36. H. Krum J.J. McMurray 2002 Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol 39 1567 1573 10.1016/S0735- 1097(02)01827-2 1:CAS:528:DC%2BD38XktlGqtbY%3D 12020481 (Pubitemid 34494279)
37. S.L. Molyneux C.M. Florkowski P.M. George, et al. 2008 Coenzyme Q 10: an independent predictor of mortality in chronic heart failure J Am Coll Cardiol 52 1435 1441 10.1016/j.jacc.2008.07.044 1:CAS:528:DC%2BD1cXht12gt77J 19017509
38. M. Rauchhaus A.J. Coats S.D. Anker 2000 The endotoxin-lipoprotein hypothesis Lancet 356 930 933 10.1016/S0140-6736(00)02690-8 1:CAS:528: DC%2BD3cXmslKlsbw%3D 11036910
39. S. Sola M.Q. Mir S. Rajagopalan, et al. 2005 Statin therapy is associated with improved cardiovascular outcomes and leves of inflammatory markers in patients with heart failure J Card Fail 11 607 612 10.1016/j.cardfail.2005.05. 011 1:CAS:528:DC%2BD2MXhtFers7%2FO 16230264 (Pubitemid 41463732)
40. Deedwania PC, Cannon CP, Saperia GM: Statin therapy in patients with heart failure. Available at http://www.uptodate.com/patients/content/topic.do? topicKey=~0bbZIRnk5. Accessed February 2009.
41. S.A. Hunt W.T. Abraham M.H. Chin, et al. 2009 ACCF/AHA Practice Guideline: 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation J Am Coll Cardiol 53 e1 e90 10.1016/j.jacc.2008.11.013 19358937